The grant project is part of the company's ongoing effort to expand into pre-designed research tests for disease biomarkers and point-of-care diagnostics.
Originally published Nov. 22.
Doctors have been in a "should we or shouldn't we" conundrum with warfarin pharmacogenetic testing for years.
Direct-to-consumer genetic testing companies have based their products on what scientists have accomplished, but the caveat is that the science is still in its early days.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.